Safety of azithromycin in infants under six months of age in Niger: A community randomized trial

Catherine E Oldenburg, Ahmed M Arzika, Ramatou Maliki, Mohamed Salissou Kane, Elodie Lebas, Kathryn J Ray, Catherine Cook, Sun Y Cotter, Zhaoxia Zhou, Sheila K West, Robin Bailey, Travis C Porco, Jeremy D Keenan, Thomas M Lietman and Study Group Mordor

PLOS Neglected Tropical Diseases, 2018, vol. 12, issue 11, 1-11

Abstract: Background: Mass azithromycin distribution reduces under-5 child mortality. Trachoma control programs currently treat infants aged 6 months and older. Here, we report findings from an infant adverse event survey in 1–5 month olds who received azithromycin as part of a large community-randomized trial in Niger. Methods and principal findings: Active surveillance of infants aged 1–5 months at the time of treatment was conducted in 30 randomly selected communities from within a large cluster randomized trial of biannual mass azithromycin distribution compared to placebo to assess the potential impact on child mortality. We compared the distribution of adverse events reported after treatment among azithromycin-treated versus placebo-treated infants. From January 2015 to February 2018, the caregivers of 1,712 infants were surveyed. Approximately one-third of caregivers reported at least one adverse event (azithromycin: 29.6%, placebo: 34.3%, risk ratio [RR] 0.86, 95% confidence interval [CI] 0.68 to 1.10, P = 0.23). The most commonly reported adverse events included diarrhea (azithromycin: 19.3%, placebo: 28.1%, RR 0.68, 95% CI 0.49 to 0.96, P = 0.03), vomiting (azithromycin: 15.9%, placebo: 21.0%, RR 0.76, 95% CI 0.56 to 1.02, P = 0.07), and skin rash (azithromycin: 12.3%, placebo: 13.6%, RR 0.90, 95% CI 0.59 to 1.37, P = 0.63). No cases of infantile hypertrophic pyloric stenosis were reported. Conclusions: Azithromycin given to infants aged 1–5 months appeared to be safe. Inclusion of younger infants in larger azithromycin-based child mortality or trachoma control programs could be considered if deemed effective. Trial registration: ClinicalTrials.gov NCT02048007. Author summary: Trachoma control programs currently treat all adults and children age 6 months and older in communities endemic for trachoma. If shown to be safe, programs could consider inclusion of younger children in mass treatment programs. Here, we evaluated adverse events in infants aged 1–5 months who were participating in a placebo-controlled trial of mass azithromycin for the reduction of child mortality in Niger. Overall, there was no difference in the frequency of adverse events among children treated with azithromycin compared to placebo. Common adverse events in both arms included diarrhea, vomiting, and skin rash. Azithromycin distribution to children between 1 and 5 months of age appeared to be safe. Inclusion of younger children in azithromycin-based trachoma and child mortality programs could be considered.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006950 (text/html)
https://journals.plos.org/plosntds/article/file?id ... 06950&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pntd00:0006950

DOI: 10.1371/journal.pntd.0006950

Access Statistics for this article

More articles in PLOS Neglected Tropical Diseases from Public Library of Science
Bibliographic data for series maintained by plosntds ().